Company news

Inovio Pharmaceuticals, Inc. news in 2025

Inovio Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

December 29, 2025

INOVIO Reports Inducement Grant Under Inducement Plan

December 19, 2025

INOVIO to Participate in December Investor Conferences

November 18, 2025

INOVIO Announces Pricing of $25 Million Public Offering

November 11, 2025

INOVIO Announces Proposed Public Offering

November 10, 2025

INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 10, 2025

INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults

November 3, 2025

INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025

October 27, 2025

INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

October 23, 2025

Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine

October 21, 2025

INOVIO to Participate in Upcoming Scientific Conferences

September 25, 2025

INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults

August 26, 2025

INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

August 25, 2025

INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 12, 2025

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

August 11, 2025

INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025

August 4, 2025

INOVIO to Present at Upcoming Scientific Conference

July 7, 2025

INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 13, 2025

INOVIO to Present at Upcoming Scientific and Investor Conferences

April 30, 2025

INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

April 29, 2025

INOVIO to Present at Upcoming Scientific Conferences

April 9, 2025

INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

March 18, 2025

INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19

March 13, 2025

INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

March 12, 2025

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

February 11, 2025

Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

February 9, 2025

INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

January 28, 2025

INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

January 8, 2025

Calls in 2025

Decks in 2025